RxDoctor Payments Data

Syed Husain, MD

Infectious Disease · Hamilton, NJNPI 1326054008

Payments from drug & device makers

$4,153in general payments, 2019–2025

Across 277 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$1K
  • Gilead$976
  • Merck$508
  • AbbVie$284
  • Paratek Pharmaceuticals, Inc.$249
  • Johnson & Johnson$227
  • plus $528 from 10 others

What the payments were for

  • Food & beverage$4,153100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,153 in reported general payments places this provider in the 75th percentile of 334 infectious disease providers in New Jersey.

See all infectious disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$101,971
Medicare patients
325
Services billed
907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala132$542,256
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf46$210,497
JulucaDolutegravir/Rilpivirine53$183,488
PrezcobixDarunavir/Cobicistat48$124,603
TivicayDolutegravir Sodium51$117,647
DescovyEmtricitabine/Tenofov Alafenam49$114,692
GenvoyaElviteg/Cob/Emtri/Tenof Alafen23$108,502
DovatoDolutegravir Sodium/Lamivudine21$68,819
IsentressRaltegravir Potassium23$47,616
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$45,078
Isentress HdRaltegravir Potassium22$44,658
TriumeqAbacavir/Dolutegravir/Lamivudi11$40,204
Darunavir30$26,956
Maraviroc14$17,287
EdurantRilpivirine Hcl11$16,759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$976$765,450204 claims
Viiv Healthcare CompanyJuluca, Tivicay, Dovato, Triumeq$1,381$410,158136 claims
Janssen Products, LPSymtuza$14$210,49746 claims
Johnson & JohnsonPrezcobix$227$124,60348 claims
MerckIsentress, Isentress Hd$508$92,27445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 334 infectious disease providers in New Jersey.

Other infectious disease in Hamilton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →